{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:52:13Z","timestamp":1774929133935,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.suc.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T23:16:51Z","timestamp":1629847011000},"page":"1033-1044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Controversies in Breast Cancer Surgery"],"prefix":"10.1016","volume":"101","author":[{"given":"Lily","family":"Gutnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwadamilola M.","family":"Fayanju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.suc.2021.06.002_bib1","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1056\/NEJMsr1504363","article-title":"Breast-cancer screening--viewpoint of the IARC Working Group","volume":"372","author":"Lauby-Secretan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.suc.2021.06.002_bib2","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1158\/1055-9965.EPI-15-0293","article-title":"Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status","volume":"24","author":"Chen","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.suc.2021.06.002_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jacr.2016.07.034","article-title":"Racial disparities in screening mammography in the united states: a systematic review and meta-analysis","volume":"14","author":"Ahmed","year":"2017","journal-title":"J\u00a0Am Coll Radiol"},{"issue":"13","key":"10.1016\/j.suc.2021.06.002_bib4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","article-title":"HER2 and breast cancer\u2014a phenomenal success story","volume":"381","author":"Hayes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.suc.2021.06.002_bib5","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/cncr.29348","article-title":"Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States","volume":"121","author":"Mougalian","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2021.06.002_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/IJWH.S82816","article-title":"Contralateral prophylactic mastectomy: current perspectives","volume":"8","author":"Yao","year":"2016","journal-title":"Int J Womens Health"},{"issue":"3","key":"10.1016\/j.suc.2021.06.002_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1245\/s10434-019-08038-8","article-title":"Contralateral prophylactic mastectomy use after neoadjuvant chemotherapy","volume":"27","author":"Christian","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.suc.2021.06.002_bib8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djq088","article-title":"Assessing women at high risk of breast cancer: a review of risk assessment models","volume":"102","author":"Amir","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.suc.2021.06.002_bib9","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2010.32.7395","article-title":"Declining incidence of contralateral breast cancer in the United States from 1975 to 2006","volume":"29","author":"Nichols","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2021.06.002_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.breast.2016.04.005","article-title":"Contralateral prophylactic mastectomy (CPM): a systematic review of patient reported factors and psychological predictors influencing choice and satisfaction","volume":"28","author":"Ager","year":"2016","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.suc.2021.06.002_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1245\/s10434-016-5688-z","article-title":"Society of surgical oncology breast disease working group statement on prophylactic (Risk-Reducing) mastectomy","volume":"24","author":"Hunt","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.suc.2021.06.002_bib12","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1245\/s10434-014-3930-0","article-title":"Survival analysis of contralateral prophylactic mastectomy: a question of selection bias","volume":"21","author":"Kruper","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.suc.2021.06.002_bib13","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1245\/s10434-010-1091-3","article-title":"Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007","volume":"17","author":"Yao","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.suc.2021.06.002_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/SLA.0000000000001698","article-title":"Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer","volume":"265","author":"Wong","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.suc.2021.06.002_bib15","article-title":"Risk-reducing mastectomy for the prevention of primary breast cancer","volume":"4","author":"Carbine","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.suc.2021.06.002_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/jamasurg.2017.0115","article-title":"State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004-2012","volume":"152","author":"Nash","year":"2017","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.suc.2021.06.002_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00266-019-01582-4","article-title":"Trends in contralateral prophylactic mastectomy","volume":"44","author":"Fairbairn","year":"2020","journal-title":"Aesthet Plast Surg"},{"issue":"3","key":"10.1016\/j.suc.2021.06.002_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-013-2643-6","article-title":"Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research","volume":"140","author":"Tracy","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.suc.2021.06.002_bib19","article-title":"Nipple- and areola-sparing mastectomy for the treatment of breast cancer","volume":"11","author":"Mota","year":"2016","journal-title":"Cochrane database Syst Rev"},{"issue":"1","key":"10.1016\/j.suc.2021.06.002_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1245\/s10434-020-09052-x","article-title":"The landmark series: mastectomy trials (skin-sparing and nipple-sparing and reconstruction landmark trials)","volume":"28","author":"Elmore","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"15_suppl","key":"10.1016\/j.suc.2021.06.002_bib21","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1200\/jco.2011.29.15_suppl.6010","article-title":"Correlates of contralateral prophylactic mastectomy in a population-based sample","volume":"29","author":"Hawley","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2021.06.002_bib22","series-title":"American Society of Plastic Surgeons","year":"2018"},{"key":"10.1016\/j.suc.2021.06.002_bib23","first-page":"e44","article-title":"A\u00a0comparison of postoperative outcomes in immediate versus delayed reconstruction after mastectomy","volume":"15","author":"Sanati-Mehrizy","year":"2015","journal-title":"Eplasty"},{"key":"10.1016\/j.suc.2021.06.002_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.breast.2017.10.009","article-title":"Outcomes of immediate versus delayed breast reconstruction: results of a multicenter prospective study","volume":"37","author":"Yoon","year":"2018","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.suc.2021.06.002_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/ejso.1999.0733","article-title":"The psychological impact of immediate rather than delayed breast reconstruction","volume":"26","author":"Al-Ghazal","year":"2000","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.suc.2021.06.002_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00006534-199307000-00011","article-title":"Various methods of breast reconstruction after mastectomy: an economic comparison","volume":"92","author":"Elkowitz","year":"1993","journal-title":"Plast Reconstr Surg"},{"issue":"5","key":"10.1016\/j.suc.2021.06.002_bib27","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/PRS.0000000000003282","article-title":"US epidemiology of breast implant\u2013associated anaplastic large cell lymphoma","volume":"139","author":"Doren","year":"2017","journal-title":"Plast Reconstr Surg"},{"issue":"6","key":"10.1016\/j.suc.2021.06.002_bib28","doi-asserted-by":"crossref","first-page":"124e","DOI":"10.1097\/PRS.0b013e318213a2e6","article-title":"Breast reconstruction after breast cancer","volume":"127","author":"Serletti","year":"2011","journal-title":"Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.suc.2021.06.002_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bjps.2019.09.040","article-title":"Autologous versus implant-based breast reconstruction: a systematic review and meta-analysis of Breast-Q patient-reported outcomes","volume":"73","author":"Toyserkani","year":"2020","journal-title":"J\u00a0Plast Reconstr Aesthet Surg"},{"issue":"3","key":"10.1016\/j.suc.2021.06.002_bib30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0014-2964(80)90352-7","article-title":"Combined chemotherapy and radiotherapy for locally advanced breast cancer","volume":"16","author":"Rubens","year":"1980","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.suc.2021.06.002_bib31","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.suc.2021.06.002_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9938","key":"10.1016\/j.suc.2021.06.002_bib33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.suc.2021.06.002_bib34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","article-title":"The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the national cancer data base (NCDB)","volume":"268","author":"Fayanju","year":"2018","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.suc.2021.06.002_bib35","article-title":"Preoperative chemotherapy for women with operable breast cancer","author":"van der Hage","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.suc.2021.06.002_bib36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-020-06012-7","article-title":"Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer","volume":"186","author":"Prakash","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.suc.2021.06.002_bib37","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/JCO.2009.25.3286","article-title":"Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Caudle","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.suc.2021.06.002_bib38","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.suc.2021.06.002_bib39","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","article-title":"Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.suc.2021.06.002_bib40","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1245\/s10434-019-07785-y","article-title":"Patterns of axillary management in stages 2 and 3 hormone receptor-positive breast cancer by initial treatment approach","volume":"26","author":"Weiss","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"18","key":"10.1016\/j.suc.2021.06.002_bib41","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2001.19.18.3808","article-title":"Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and\/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial","volume":"19","author":"Ellis","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.suc.2021.06.002_bib42","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"Smith","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.suc.2021.06.002_bib43","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"Ellis","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.suc.2021.06.002_bib44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.breast.2013.03.002","article-title":"Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: a randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy","volume":"22","author":"Hojo","year":"2013","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.suc.2021.06.002_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.soc.2017.07.008","article-title":"Neoadjuvant endocrine therapy: who benefits most?","volume":"27","author":"Grossman","year":"2018","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"10.1016\/j.suc.2021.06.002_bib46","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(11)70373-4","article-title":"Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial","volume":"13","author":"Masuda","year":"2012","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.suc.2021.06.002_bib47","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2020.38.15_suppl.504","article-title":"ALTERNATE: neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: alliance A011106","volume":"38","author":"Ma","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.suc.2021.06.002_bib48","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2021.06.002_bib49","series-title":"Resource for management options of breast cancer during COVID-19","year":"2020"},{"issue":"3","key":"10.1016\/j.suc.2021.06.002_bib50","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10549-020-05644-z","article-title":"Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium","volume":"181","author":"Dietz","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.suc.2021.06.002_bib51","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.suc.2021.06.002_bib52","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.suc.2021.06.002_bib53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"Giuliano","year":"2016","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.suc.2021.06.002_bib54","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.suc.2021.06.002_bib55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2011.1034","article-title":"Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer","volume":"306","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.suc.2021.06.002_bib56","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","article-title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial","volume":"19","author":"Galimberti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.suc.2021.06.002_bib57","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.suc.2021.06.002_bib58","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.breast.2017.08.006","article-title":"Sentinel node biopsy in early breast cancer. A review on recent and ongoing randomized trials","volume":"36","author":"Esposito","year":"2017","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.suc.2021.06.002_bib59","first-page":"552","article-title":"NCCN guidelines updates: breast cancer","volume":"17","author":"Telli","year":"2019","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"7","key":"10.1016\/j.suc.2021.06.002_bib60","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.suc.2021.06.002_bib61","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.suc.2021.06.002_bib62","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.suc.2021.06.002_bib63","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.suc.2021.06.002_bib64","doi-asserted-by":"crossref","first-page":"TPS600","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS600","volume":"37","author":"Mamounas","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.suc.2021.06.002_bib65","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2005.01.5784","article-title":"Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93","volume":"24","author":"Rudenstam","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.suc.2021.06.002_bib66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1245\/s10434-010-1217-7","article-title":"Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up","volume":"18","author":"Martelli","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.suc.2021.06.002_bib67","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10549-017-4528-6","article-title":"Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt","volume":"167","author":"Dominici","year":"2018","journal-title":"Breast Cancer Res Treat"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610921000827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610921000827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:12:36Z","timestamp":1758539556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610921000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0039610921000827"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2021.06.002","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in Breast Cancer Surgery","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}